Investors Overview

Investors Overview

Our Mission

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

Learn more about BD

News Releases

02/22/2021

Summary Toggle BD Announces Collaboration for At-Home Rapid Test for COVID-19

Aims to Pair BD Antigen Test with Scanwell Health Mobile App FRANKLIN LAKES, N.J. , Feb. 22, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, and Scanwell Health , a leader in smartphone-enabled at-home medical tests, today

PDF Version
02/12/2021

Summary Toggle BD to Present at Upcoming Investor Conferences

FRANKLIN LAKES, N.J. , Feb. 12, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences: The Leerink Virtual 10th Annual Global Healthcare

PDF Version
02/12/2021

Summary Toggle BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test

New single test for the BD MAX™ System also shows ability to detect U.K., South African Variants FRANKLIN LAKES, N.J. , Feb. 12, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced that the U.S.

PDF Version
02/04/2021

Summary Toggle BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance

- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. - BD's COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis.

PDF Version 781.8 KB
02/02/2021

Summary Toggle First-of-its-Kind Randomized Clinical Trial Published in "The Lancet Infectious Diseases" Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters

- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes - Compared with standard approaches, the BD vascular care solution reduced the relative risk of

PDF Version
01/26/2021

Summary Toggle BD Names CEO Tom Polen as Chairman of the Board

Polen to Succeed Vince Forlenza Effective April 28 FRANKLIN LAKES, N.J. , Jan. 26, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen , BD CEO and president, will assume additional responsibility as chairman

PDF Version